969 ENHANCEMENT OF ANTI-TUMOR ACTIVITY BY INITIAL CONCURRENT TREATMENT WITH ZOLEDRONIC ACID AND HORMONAL THERAPY FOR BONE-METASTATIC PROSTATE CANCER IN MULTICENTER CLINICAL TRIAL

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (III)1 Apr 2013969 ENHANCEMENT OF ANTI-TUMOR ACTIVITY BY INITIAL CONCURRENT TREATMENT WITH ZOLEDRONIC ACID AND HORMONAL THERAPY FOR BONE-METASTATIC PROSTATE CANCER IN MULTICENTER CLINICAL TRIAL Hiroji Uemura, Masahiro Yanagisawa, Ichiro Ikeda, Kiyoshi Fujinami, Sumio Noguchi, Kazumi Noguchi, and Yoshinobu Kubota Hiroji UemuraHiroji Uemura Yokohama, Japan More articles by this author , Masahiro YanagisawaMasahiro Yanagisawa Yokohama, Japan More articles by this author , Ichiro IkedaIchiro Ikeda Yokohama, Japan More articles by this author , Kiyoshi FujinamiKiyoshi Fujinami Chigasaki, Japan More articles by this author , Sumio NoguchiSumio Noguchi Yokosuka, Japan More articles by this author , Kazumi NoguchiKazumi Noguchi Yokohama, Japan More articles by this author , and Yoshinobu KubotaYoshinobu Kubota Yokohama, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.550AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Zoledronic acid (ZOL) has been widely utilized for the prevention of skeletal-related events (SREs) in patients with bone metastases who have undergone hormonal therapy for prostate cancer. With regard to preventing SREs and improving patient's quality of life, many clinical investigations using ZOL have been performed in castration-resistant prostate cancer patients. To ascertain the anti-tumor effect of ZOL treatment on clinical outcomes in patients with bone metastatic prostate cancer, we examined the effect of ZOL started simultaneously with hormonal therapy as initial treatment in patients with bone metastatic prostate cancer. METHODS Forty-seven patients with bone-metastatic prostate cancer who received an LH-RH analogue and an anti-androgen (maximum androgen blockade: MAB) were assigned to receive ZOL (4 mg intravenous administration every month for 2 years). The time to progression of PSA (TTP), overall survival (OS) and the rate of PSA decrease in patients with MAB and ZOL treatment (ZOL group) were compared with those in patients who received only MAB at one institute as a control group (non-ZOL group). RESULTS Although the nadir PSA level and the rate of PSA normalization showed no significant difference in the ZOL and non-ZOL groups, the time to nadir PSA in the ZOL group was significantly shorter than that in the non-ZOL group (P<0.05, Mann-Whitney's U test). There was a significant difference in TTP (P=0.017, log-rank test) between the ZOL and non-ZOL groups, and statistically significant differences in TTP and OS between the ZOL and non-ZOL groups (P=0.044 and 0.035, log-rank test) were recognized particularly in patients with high extent of disease (EOD) of grade 3 and 4. CONCLUSIONS Simultaneous administration of ZOL and MAB as initial treatment delayed TTP in bone-metastatic prostate cancer patients. Initial treatment with ZOL has the possibility of anti-tumor activity to delay disease progression. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e398 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiroji Uemura Yokohama, Japan More articles by this author Masahiro Yanagisawa Yokohama, Japan More articles by this author Ichiro Ikeda Yokohama, Japan More articles by this author Kiyoshi Fujinami Chigasaki, Japan More articles by this author Sumio Noguchi Yokosuka, Japan More articles by this author Kazumi Noguchi Yokohama, Japan More articles by this author Yoshinobu Kubota Yokohama, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...